The aim of this international, multicenter study was to evaluate the clinical performance of the three CE-marked VIDAS® dengue immunoassays: VIDAS® DENGUE NS1 Ag (DEAG), VIDAS® Anti-DENGUE IgM (DENM), and VIDAS® Anti-DENGUE IgG (DENG) in the main dengue-endemic regions of the world (Asia, Latin America, and Africa). The gene discussed is CD40LG; the disease is dengue disease.